Volume 2 | Issue 4 | DOI: https://doi.org/10.33696/immunology.2.039
Allicin as an Adjunct Immunotherapy against Tuberculosis
- 1Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India
- 2International Centre for Genetic Engineering and Biotechnology, New Delhi, India
Ved Prakash Dwivedi, email@example.com
Received Date: May 04, 2020
Accepted Date: June 02, 2020
Fatima S, Dwivedi VP. Allicin as an Adjunct Immunotherapy against Tuberculosis. J Cell Immunol. 2020; 2(4): 178-182.
Copyright: © 2020 Fatima S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Allicin, Garlic, Tuberculosis, T cells, Immunomodulation, DOTS, Anti-oxidant, Anti-bacterial
Multidirectional Benefits of Nanotechnology in the Diagnosis, Treatment and Prevention of Tuberculosis
Despite the curious advancement in medical science and therapeutics, tuberculosis (TB) persist the primary factor of mortality than any other infectious disease and socioeconomic disaster for millions of people around the world. According to the World Health Organization (WHO), World’s One-third of the population is infected with this disease and of these, 8 to 10 million people develop active disease and 2 million people die each year and the rest of the infected people remain asymptomatic.
The recently published manuscript entitled “Epigenetically Altered T Cells Contribute to Lupus Flares” summarizes recent advances in our understanding of how the environment alters the immune system to cause flares of systemic lupus erythematosus (SLE) in genetically predisposed people, and why it affects women approximately 9 times more often than men
In 1989, researchers proposed an intricate strategy in the field of adoptive cell therapy (ACT). Using the T-cell receptor (TCR) as a template, they replaced the coding sequence for the Vα and Vβ chains with the antigen- recognition domains from an antibody (VH and VL chains).
Over the last 10 to 15 years the treatment of patients with hematologic malignancies has seen the blossom of a large number of new agents and even new treatment strategies. Monoclonal antibodies (MoAb), TKI inhibitors, checkpoint inhibitors have been introduced in the daily clinical practice and contributed significantly to the improvement of the outcome of hematologic patients. Along with the development of these new drugs, cellular therapies, namely chimeric antigen receptor-engineered T (CART) cells, have revolutionized the therapeutic paradigm of patients with B-cell lymphoid malignancies and acute lymphoblastic leukemia (ALL).
Allicin (diallylthiosulfinate) is a volatile, oxygenated, sulphur-containing compound, extracted from garlic (Allium sativum). It is responsible for the characteristic odor of garlic. Allicin is known to exert its effects as an antipathogenic agent mainly by targeting the thiol-containing proteins or enzymes in different microorganisms and also by regulating the key genes responsible for the virulence of the microorganism.